Hosted on MSN
Inside a cell therapy manufacturing facility: How Iovance turns a patient’s immune cells into treatment
Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The 71-year-old grandfather with metastatic melanoma had flown in from ...
Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy ...
Personalized cell therapies have emerged as powerful treatments for cancers and other diseases but producing them remains a complex engineering challenge. Unlike conventional drugs, each cell therapy ...
The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to ...
In this webinar, Gonçalo Regalo discusses how raw materials, media composition, and process design influence scalable cell ...
Cellares has raised a $257 million Series D financing, bringing its total funding to $612 million. The latest comes as the cell therapy manufacturing company accelerates plans to industrialize ...
Cell and gene therapies (CGTs) are built on living systems. From early research through commercial distribution, the integrity of those systems depends on the ability to preserve cells without ...
Cell therapy manufacturing has long been constrained by manual bottlenecks - steps that are labor-intensive, variable, and difficult to scale. Robotic automation is increasingly becoming key to ...
Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. "This is a quantum leap in ...
In cell therapy applications, commonly employed cell purification platforms for large-scale isolation of immune or stem cells separate cells based on a single cell surface antigen. Enrichment based on ...
Standardizing cell therapy production will require a combination of AI, automation, and innovative bioprocessing technologies ...
New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical production to support the development of cell therapies for cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results